TFDP3 and acute lymphoblastic leukemia: Our data showed that TFDP3 confers chemoresistance in MRD within childhood T-ALL, indicating that targeting TFDP3 is a potential strategy for overcoming chemoresistance in minimal residual cancer cells, and stop progression to relapse and metastatic disease.